Mother's immune cells could help fight severe CMV in newborns
NCT ID NCT05564598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding special immune cells from the mother to standard antiviral medicine can safely and more effectively treat moderate to severe CMV infection in newborns. Babies up to 21 days old with confirmed CMV disease may join. All receive antiviral drugs, and some also get the mother's CMV-fighting cells. The goal is to see if the combination clears the virus better and is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL CYTOMEGALOVIRAL (CMV) DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Los Angeles
RECRUITINGLos Angeles, California, 90027, United States
-
Nationwide Children's Hosptial
RECRUITINGColumbus, Ohio, 43205, United States
-
New York Medical College
RECRUITINGValhalla, New York, 10595, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63130, United States